Flares of Systemic Autoimmune Rheumatic Disease Following Coronavirus Disease 2019 Vaccination: A Narrative Review

Overview

Journal Rheum Dis Clin North Am

Publisher Elsevier

Specialty Rheumatology

Date 2024 Nov 16

PMID 39550108

Authors

Genna Braverman

Medha Barbhaiya

Minerva Nong

Lisa A Mandl

Affiliations

Soon will be listed here.

Abstract

This narrative review summarizes current evidence on the risk of systemic autoimmune rheumatic disease (SARD) flare following coronavirus disease 2019 vaccination. The authors detail key studies in the literature employing diverse methodologies, including cross-sectional surveys, prospective and retrospective cohorts, case-crossover designs, self-controlled case series, and systematic reviews. Data are reassuring, suggesting that vaccination is unlikely to increase the risk of flares across a range of SARD. When postvaccination flares do occur, individuals with high disease activity and frequent flares at baseline may be at higher risk. Rheumatologists may consider discussing these findings with patients during collaborative conversations about risks and benefits of vaccination.

References

Zavala-Flores E, Salcedo-Matienzo J, Huamanchumo-Guzman R, Berrocal-Kasay A, Alarcon G . A 12-month follow-up study of patients with systemic lupus erythematosus after immunization against SARS-CoV-2. Lupus. 2024; 33(3):282-288. DOI: 10.1177/09612033241227811. View

Braverman G, Barbhaiya M, Nong M, Bykerk V, Hupert N, Lewis 5th C . Association of COVID-19 Vaccinations With Flares of Systemic Rheumatic Disease: A Case-Crossover Study. Arthritis Care Res (Hoboken). 2024; 76(5):733-742. PMC: 11039379. DOI: 10.1002/acr.25288. View

Putman M, Kennedy K, Sirotich E, Liew J, Sattui S, Moni T . COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. Lancet Rheumatol. 2022; 4(4):e237-e240. PMC: 8824526. DOI: 10.1016/S2665-9913(22)00001-7. View

Chehab G, Richter J, Brinks R, Fischer-Betz R, Winkler-Rohlfing B, Schneider M . Vaccination coverage in systemic lupus erythematosus-a cross-sectional analysis of the German long-term study (LuLa cohort). Rheumatology (Oxford). 2018; 57(8):1439-1447. DOI: 10.1093/rheumatology/key120. View

Holladay E, Mudano A, Xie F, Stewart P, Jackson L, Danila M . COVID-19 Vaccine Uptake, Hesitancy, and Flare in a Large Rheumatology Practice Network. Arthritis Care Res (Hoboken). 2023; 76(1):111-119. DOI: 10.1002/acr.25241. View

Sood A, Tran M, Murthy V, Gonzalez E . Immunogenicity and Safety of SARS-CoV-2 Vaccination in Patients With Rheumatic Diseases: A Systematic Review and Meta-analysis. J Clin Rheumatol. 2022; 28(8):381-389. DOI: 10.1097/RHU.0000000000001871. View

Christopher-Stine L, Wan G, Kelly W, McGowan M, Bostic R, Reed M . Patient-reported dermatomyositis and polymyositis flare symptoms are associated with disability, productivity loss, and health care resource use. J Manag Care Spec Pharm. 2020; 26(11):1424-1433. PMC: 10391285. DOI: 10.18553/jmcp.2020.26.11.1424. View

Felten R, Kawka L, Dubois M, Ugarte-Gil M, Fuentes-Silva Y, Piga M . Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study. Lancet Rheumatol. 2021; 3(9):e613-e615. PMC: 8294805. DOI: 10.1016/S2665-9913(21)00221-6. View

Harrison N, Poeppl W, Miksch M, Machold K, Kiener H, Aletaha D . Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases. Vaccine. 2018; 36(32 Pt B):4875-4879. DOI: 10.1016/j.vaccine.2018.06.065. View

10.

Tedeschi S, Ellrodt J, Stratton J, Santacroce L, Chandler P, Gravallese E . Acceptability of Vaccines Against Preventable Infections Including Coronavirus Disease 2019 Among Patients With Rheumatic Disease. ACR Open Rheumatol. 2021; 4(1):3-7. PMC: 8652709. DOI: 10.1002/acr2.11351. View

11.

DSilva K, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace Z . COVID-19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study. Arthritis Rheumatol. 2020; 73(6):914-920. PMC: 8169514. DOI: 10.1002/art.41619. View

12.

Fong W, Woon T, Chew L, Low A, Law A, Poh Y . Prevalence and factors associated with flares following COVID-19 mRNA vaccination in patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: a national cohort study. Adv Rheumatol. 2023; 63(1):38. DOI: 10.1186/s42358-023-00316-0. View

13.

Shaw Y, Hustek S, Nguyen N, Starlin M, Wipfler K, Wallace B . Rheumatic disease patient decision-making about COVID-19 vaccination: a qualitative analysis. BMC Rheumatol. 2022; 6(1):76. PMC: 9706890. DOI: 10.1186/s41927-022-00307-6. View

14.

Duculan R, Mancuso C . Perceived Risk of SARS-CoV-2 at the Start of the COVID-19 Pandemic and Subsequent Vaccination Attitudes in Patients With Rheumatic Diseases: A Longitudinal Analysis. J Clin Rheumatol. 2022; 28(4):190-195. PMC: 9169604. DOI: 10.1097/RHU.0000000000001826. View

15.

Svensson A, Emborg H, Bartels L, Ellingsen T, Adelsten T, Cordtz R . Outcomes following SARS-CoV-2 infection in individuals with and without inflammatory rheumatic diseases: a Danish nationwide cohort study. Ann Rheum Dis. 2023; 82(10):1359-1367. DOI: 10.1136/ard-2023-223974. View

16.

Yoshida T, Tsuji H, Onishi A, Takase Y, Shirakashi M, Onizawa H . Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus. Lupus Sci Med. 2022; 9(1). PMC: 9378947. DOI: 10.1136/lupus-2022-000727. View

17.

De Stefano L, Balduzzi S, Bogliolo L, DOnofrio B, di Lernia M, Mauric E . Reactogenicity, safety and disease flares following BNT162b2 mRNA COVID-19 vaccine in patients with chronic immune-inflammatory arthritis treated with biological and targeted synthetic disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol. 2022; 41(3):667-675. DOI: 10.55563/clinexprheumatol/0ltj1i. View

18.

Jackson L, Anderson E, Rouphael N, Roberts P, Makhene M, Coler R . An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020; 383(20):1920-1931. PMC: 7377258. DOI: 10.1056/NEJMoa2022483. View

19.

Li X, Tong X, Yeung W, Kuan P, Yum S, Chui C . Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong. Ann Rheum Dis. 2021; 81(4):564-568. PMC: 8550868. DOI: 10.1136/annrheumdis-2021-221571. View

20.

Jagtap K, Naveen R, Day J, Sen P, Vaidya B, Nune A . Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period-a cross-sequential study based on COVAD surveys. Rheumatology (Oxford). 2023; 62(12):3838-3848. DOI: 10.1093/rheumatology/kead144. View